Literature DB >> 6291808

An improved radioreceptor assay for TSH receptor antibodies.

G Shewring, B R Smith.   

Abstract

An improved receptor assay for TSH receptor antibodies is described in which detergent-solubilized TSH receptors and 125I-labelled TSH are used. Normal human serum and immunoglobulin concentrates from normal serum showed little effect on the interaction between labelled TSH and detergent-solubilized receptors whereas immunoglobulin concentrates from some Graves sera caused marked inhibition of TSH binding. Precipitation with polyethylene glycol was the most convenient way of preparing immunoglobulin concentrates and using this technique the assay could be completed in a few hours. The coefficient of inter assay variation at 51% inhibition of labelled TSH binding was 3.7% and analysis of serum samples from patients with Graves' disease (n = 42), Hashimoto's disease (n = 26), multinodular goitre (n = 9), rheumatoid arthritis (n = 10) and normal donors (n = 35) suggested that the assay could detect TSH receptor antibodies in about 80% of patients (treated and untreated) with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291808     DOI: 10.1111/j.1365-2265.1982.tb01607.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  43 in total

1.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.

Authors:  X M Yan; J Guo; P Pichurin; K Tanaka; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Autoimmune thyroid disease accompanied by recurring episodes of painful thyroid ameliorated by thyroidectomy.

Authors:  S Konno; N Konno; M Yokobori; K Kazui; T Hase; T Uematsu; M Nishimura
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

3.  Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies.

Authors:  T Akamizu; S Ikuyama; M Saji; S Kosugi; C Kozak; O W McBride; L D Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.

Authors:  K Kazuo; T Fujikado; G Ohmi; J Hosohata; Y Tano
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

5.  Clinical significance of anti-TSH antibody in sera from patients with Graves' disease and other thyroid disorders.

Authors:  T Akamizu; T Mori; H Imura; J Noh; N Hamada; K Ito; Y Koizumi; T Yamada; T Fujihira; S Eto
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

6.  Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.

Authors:  J Ginsberg; C von Westarp
Journal:  CMAJ       Date:  1986-05-15       Impact factor: 8.262

7.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

8.  Differential immunosuppressive action of carbimazole and propylthiouracil.

Authors:  R Wilson; J H McKillop; C Pearson; A K Burnett; J A Thomson
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

9.  Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.

Authors:  R Hörmann; B Saller; R Müller; K Mann
Journal:  Klin Wochenschr       Date:  1985-12-16

10.  Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies.

Authors:  T Diana; C Wüster; M Kanitz; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2016-05-19       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.